Articles

Guest Commentary: Should you be concerned about temporary data?

As regulatory agencies evolve their thinking around data integrity mandates, the guidance is pointing to curbing the ability to alter data in temporary memory before it becomes permanent
Written byJeff Vannest and LabVantage
| 3 min read

If someone says data integrity isn’t a new issue, they might not be paying attention to the matter of temporary data. While it’s been two years since the World Health Organization announced its good data and record management practices, and only a year since the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) issued draft guidance to improve data integrity, one aspect is gaining attention: that of temporary memory. While these regulatory agencies evolve their thinking around data integrity mandates, the guidance is pointing to curbing the ability to alter data in temporary memory before it becomes permanent.

The issue of temporary data

Because data is central to a regulator’s mission to ensure the safety, efficacy and quality of pharmaceuticals, regulatory agencies such as FDA and MHRA seek to ensure that data submitted to them has not been falsified, omitted, hidden or substituted. This includes data points that have been entered, but perhaps never saved.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Abstract illustration of colorful spectral emission peaks.
As flow cytometry panels grow larger and more complex, thoughtful panel design has become critical for experimental success.
A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.